J&J, Rallybio partner on drug development for rare fetal condition.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      JOHNSON & Johnson (Company) JNJ
    • Abstract:
      Johnson & Johnson (J&J) has partnered with biotechnology company Rallybio to develop new treatments for fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare disorder that can be life-threatening for infants. Rallybio will receive $6.6 million in equity investment from J&J's venture capital arm and plans to start a Phase 2 trial for its antibody, RLYB212, later this year. J&J will also provide funding to raise awareness about its own drug, nipocalimab, which is being tested as a treatment for pregnant individuals who have developed antibodies that can harm the fetus. Rallybio is also conducting a natural history study to better understand the disease and its manifestations across different races and ethnicities. [Extracted from the article]
    • Abstract:
      Copyright of BioPharma Dive is the property of Industry Dive and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)